Related Experiment Videos
Stenotrophomonas maltophilia pneumonia in a premature infant
1Department of Pediatrics, Dokuz Eylül University Faculty of Medicine, Izmir.
Abstract:
Stenotrophomonas (Xanthomonas) maltophilia is an aerobic, non-fermentative, gram-negative bacillus that is generally considered an opportunistic pathogen. Infections due to S. maltophilia have become increasingly important in the hospital environment. Patients compromised by debilitating illnesses, surgical procedures or indwelling vascular catheters are most prone to S. maltophilia infections. To our knowledge, we report the first case of S. maltophilia pneumonia in a premature infant of 31 weeks gestational age. Although the therapy of choice for severe infections caused by S. maltophilia remains to be decided, this patient was successfully treated by amikacin.
Insights
Stenotrophomonas maltophilia pneumonia is rare in premature infants. This case highlights successful amikacin treatment in a 31-week gestational age infant with S. maltophilia pneumonia.
Area of Science:
- Medical Microbiology
- Pediatric Infectious Diseases
Background:
- Stenotrophomonas maltophilia is an opportunistic pathogen increasingly implicated in hospital-acquired infections.
- Risk factors include compromised immune status, surgery, and indwelling vascular catheters.
Observation:
- A 31-week gestational age premature infant developed pneumonia.
- The infant was diagnosed with Stenotrophomonas maltophilia pneumonia.
Findings:
- This represents the first reported case of S. maltophilia pneumonia in a premature infant.
- The infant was successfully treated with amikacin.
Implications:
- This case expands the understanding of S. maltophilia as a pathogen in neonates.
- Amikacin may be an effective treatment option for S. maltophilia pneumonia in premature infants.